Clinical Trials
17 trialsNCT05000294 2026-06-05
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Recruiting
NCT06710756 2026-06-05
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT03132922 2026-06-04
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Phase 1 Active not recruiting
NCT05949632 2026-06-04
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Terminated
NCT06760819 2026-06-04
panSOHO
Bayer
Phase 2 Recruiting
NCT05039801 2026-06-01
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07124000 2026-06-01
DP-04
AstraZeneca
Recruiting
NCT07613723 2026-05-29
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
Zelluna Immunotherapy AS
Phase 1 Recruiting
NCT07614620 2026-05-29
HYPNO-AJA2
Institut Bergonié
Phase NA Not yet recruiting
NCT04514484 2026-05-28
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07259304 2026-05-28
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
University of Southern California
Recruiting
NCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03449108 2026-05-22
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05225428 2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA Recruiting
NCT06503146 2026-05-19
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04969835 2026-05-15
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences Ltd
Phase 1 Recruiting
NCT06751524 2026-05-15
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available